Delivery Order SPE2DB22D3301-SPE2DB25FZ0CN
- Not listed
- The Defense Logistics Agency awarded a $40,532.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 milliliter vials, with an ultimate completion date of August 22, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order valued at $2,937.12 to AmerisourceBergen Drug Corp for GAMUNEX-C 1 gram/10 milliliter vials on August 19, 2025, with completion targeted for September 10, 2025. This firm fixed price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global...
- The Defense Logistics Agency awarded a delivery order valued at $9,522.72 to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 milliliter vials. This is a firm fixed price contract with an ultimate completion date of August 18, 2025, and was competitively awarded without a set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $28,323.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 milliliter vials with an ultimate completion date of August 22, 2025. This non-set-aside competitive award was issued on August 1, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $7,325.64 to AmerisourceBergen Drug Corp for GAMUNEX-C, a 10 gram/100 mL immunoglobulin vial product, with an ultimate completion date of August 21, 2025. This competitive award, issued on July 31, 2025, utilizes a firm fixed price contract type with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is a...
- The Defense Logistics Agency awarded a $28,323.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of GAMUNEX-C 20 gram/200 mL vials. This non-set-aside competitive award is scheduled for completion by September 2, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9...
- The Defense Logistics Agency awarded a $13,963.20 delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 40 Gram/400 mL vials on August 15, 2025, with completion expected by September 8, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $27,926.40 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 28, 2025, and performance to be completed at the awardee's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $43,569.46 delivery order on August 21, 2025, for Gamunex-C 20 gram/200 mL vials with a completion date of September 12, 2025. This is a firm fixed-price, non-set-aside contract performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a $9,157.05 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 10 gram/100 mL vials with a completion date of August 14, 2025. This competitively awarded, non-set-aside contract represents a single delivery order sourced through AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion global pharmaceutical support vehicle running through December 2026. The product will be...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0CNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $27,143.22 to AmerisourceBergen Drug Corp for the supply of GAMUNEX-C (a 20 gram/200 mL vial immunoglobulin product) on August 27, 2025, with an ultimate completion date of September 18, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026 that authorizes the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal medical procurement vendor for the Defense Logistics Agency's medical supply chain. As a prime contractor under the DLA's Pharmaceutical Prime Vendor Global Program, the company fulfills federal requirements for specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. The company's federal contract portfolio demonstrates its capability to meet diverse and time-sensitive military healthcare procurement needs through competitive open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.1k | 8/27/25 |